PharmaCyte Biotech
PMCB
29 hedge funds and large institutions have $10.2M invested in PharmaCyte Biotech in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
2.12% more ownership
Funds ownership: 18.11% → 20.23% (+2.1%)
3% more capital invested
Capital invested by funds: $9.93M → $10.2M (+$289K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 30 → 29 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
94% less call options, than puts
Call options by funds: $44K | Put options by funds: $756K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$314K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$205K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$172K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$138K |
| 5 |
BlackRock
New York
|
+$93.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$287K |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
-$120K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$90K |
| 4 |
Jane Street
New York
|
-$60.7K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$50.3K |
PMCB Hedge Fund Activity: Q1 2023 in Review
29 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q1 2023, worth a combined $10.2M — up 2.9% from $9.93M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PMCB and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $314K. The largest seller was Sabby Management, exiting entirely with an estimated $287K sold.
- 29 institutional investors held PharmaCyte Biotech (PMCB) as of Q1 2023, down from 30 in Q4 2022.
- Funds reported $10.2M of PharmaCyte Biotech stock for Q1 2023, up 2.9% quarter-over-quarter.
- 5 funds opened new PharmaCyte Biotech positions in Q1 2023 and 6 closed out, a net change of -1 holder.
- The largest PharmaCyte Biotech buyer in Q1 2023 was Susquehanna International Group, an estimated $314K added.
- The largest PharmaCyte Biotech seller in Q1 2023 was Sabby Management, an estimated $287K sold.
Based on aggregated 13F filings for Q1 2023.